Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-Escalation Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor

NCT01082068 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01082068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01082068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-Escalation Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2010
Completion date
April 30, 2013
Enrollment
72 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer